Sign in Subscribe
T cells

Breakthrough Research Reveals Mechanistic Link Between Hybrid Insulin Peptide Formation and Disease Progression in Type 1 Diabetes

Strategic Insights

— 1 min read

Researchers from the University of Colorado Anschutz Medical Campus have made a groundbreaking discovery in understanding the mechanisms behind type 1 diabetes. By studying the formation of hybrid insulin peptides (HIPs), they found that a single leucine-to-isoleucine substitution in insulin C-peptide can significantly disrupt HIP formation in NOD mouse islets. This finding is a crucial step towards developing therapeutic targets for intervention in individuals at risk of developing type 1 diabetes.

Key Takeaways:

  • Researchers identified hybrid insulin peptides (HIPs) as targets of autoreactive T cells in type 1 diabetes, although their causal role in disease pathogenesis remained unclear.
  • Financial supporters for this research include the National Institute of Allergy and Infectious Diseases and the National Institute of Diabetes and Digestive and Kidney Diseases.
  • A single leucine-to-isoleucine substitution in insulin C-peptide significantly disrupts cathepsin D-mediated HIP formation in NOD mouse islets.
  • NOD mice engineered with this precise modification (NOD INS2I/I) showed significantly reduced HIP content, decreased T-cell reactivity, and significantly delayed diabetes onset (43% disease-free at 1 year vs. 10% in controls).
  • These findings establish a mechanistic link between HIP formation and disease progression, revealing cathepsin D-mediated transpeptidation as a potential therapeutic target for intervention in at-risk individuals.
  • The research was peer-reviewed and published in the journal Diabetes.
  • Additional authors for this research include Jason Groegler, Kelli Nicholson, Mylinh Dang, Janet Wenzlau, K. Scott Beard, Anita Hohenstein, Roger Powell, Rocky Baker, Kathryn Haskins, Jennifer Matsuda, and Thomas Delong.

Statistics:

  • 43% of NOD INS2I/I mice were disease-free at 1 year, compared to 10% of controls.
  • 10% of controls developed diabetes, compared to 57% of wild-type NOD mice.
  • The study was funded by the National Institute of Allergy and Infectious Diseases and the National Institute of Diabetes and Digestive and Kidney Diseases.
  • The research provides new insights into the mechanisms of type 1 diabetes, highlighting the potential therapeutic target of cathepsin D-mediated transpeptidation.

Sources:

  • NewsRx. Research Conducted at University of Colorado Anschutz Medical Campus Has Provided New Information about Proinsulin (Strategic Reduction of Hybrid Insulin Peptide Formation Significantly Delays Diabetes Onset in NOD Mice). Diabetes Week. November 3, 2025; p 373.
  • Strategic Reduction of Hybrid Insulin Peptide Formation Significantly Delays Diabetes Onset in NOD Mice. Diabetes, 2025.

Read more